Shopping Cart
Remove All
Your shopping cart is currently empty
Synonyms: WUCAM, VSTM3, VSIG9, T cell immunoreceptor with Ig and ITIM domains

| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 5 µg | $42 | - | In Stock | |
| 10 µg | $65 | - | In Stock | |
| 20 µg | $98 | - | In Stock | |
| 50 µg | $198 | - | In Stock | |
| 100 µg | $351 | 7-10 days | 7-10 days | |
| 200 µg | $621 | 7-10 days | 7-10 days | |
| 500 µg | $1,320 | 7-10 days | 7-10 days |
| Bioactivity | 1. Immobilized human CD155a-His at 10μg/mL (100μL/well) can bind human TIGIT-Fc, the EC50 of human TIGIT-Fc is 0.03-0.2μg/mL.
2.Loaded Recombinant Human TIGIT Protein, hFc Tag on ProA Biosensor, can bind Recombinant Human CD155/PVR Protein, His Tag with an affinity constant of 0.18 uM as determined in BLI assay (Routinely tested). |
| Description | TIGIT Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 39.2 kDa and the accession number is Q495A1-1. |
| Species | Human |
| Expression System | HEK293 Cells |
| Tag | C-hFc |
| Accession Number | Q495A1-1 |
| Construction | A DNA sequence encoding the human TIGIT (NP_776160.2) (Met1-Pro141) was expressed with the Fc region of human IgG1 at the C-terminus. Predicted N terminal: Met 22 |
| Protein Purity | ≥ 95% as determined by SDS-PAGE. ≥ 95 % as determined by SEC-HPLC. ,![]() |
| Endotoxin | < 1.0 EU/μg of the protein as determined by the LAL method. |
| Formulation | Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization. |
| Reconstitution | Reconstituted with sterile deionized water to 0.25 mg/mL. Reconstitution conditions may vary depending on the lot. |
| Synonyms | WUCAM, VSTM3, VSIG9, T cell immunoreceptor with Ig and ITIM domains |
| Research Background | TIGIT, also known as V-set and transmembrane domain-containing protein 3 (VSTM3) or V-set and immunoglobulin domain-containing protein 9 (VSIG9) is a new surface protein containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed on regulatory, memory, activated T cells and NK cells. It binds PVR with high affinity, and PVRL2 with lower affinity, but not PVRL3. Knockdown of TIGIT with siRNA in human memory T cells did not affect T cell responses, however, TIGIT inhibits NK cytotoxicity directly through its ITIM. TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. The binding of PVR to TIGIT on human dendritic cells enhanced the production of IL-1 and diminished the production of IL-12p4. Also, TIGIT counter inhibits the NK-mediated killing of tumor cells and protects normal cells from NK-mediated cytotoxicity thus providing an "alternative self" mechanism for MHC class I inhibition.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint TargetsImmunotherapyTargeted Therapy |
| Molecular Weight | 39.2 kDa (predicted); 45 kDa (reducing condition, due to glycosylation) |
| Shipping | In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice. |
| Storage | It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.